Abstract
The concept of autoimmune pancreatitis (AIP) was first reported in 1995 by Yoshida K et al. [1]. Even before this report, however, cases of AIP or chronic pancreatitis with other organ involvement such as the lacrimal glands, retroperitoneum, and biliary ducts had begun to accumulate in the literature [2–5]. Then in 2001, Hamano et al. [6] reported high serum IgG4 levels in patients with AIP, which is now a hallmark of type 1 AIP/IgG4-related disease (RD). In 2002, Yamamoto Y et al. [7] reported that patients with so-called Mikulicz’s disease, the disease ignored for nearly 50 years [8], also had high serum IgG4 levels. Then, through extensive discussion and communications among experts from different clinical fields, finally, a new concept of IgG4-RD was established by combining AIP, Mikulicz’s disease, and other diseases [9–12]. Since the concept of AIP was introduced in 1995 [1], cases of AIP have been identified not only in Japan but also in other countries, and interesting differences have been observed between AIP cases from Asia and Western countries [13–15]. In brief, AIP in Western countries occurs equally between males and females in a relatively young population and is frequently associated with inflammatory bowel disease. Importantly, no cases had elevated serum IgG4 levels. These features are quite distinct from AIP with high serum IgG4 levels seen in Japan. After extensive discussion, a consensus statement on Asian diagnostic criteria for AIP [16] and international consensus diagnostic criteria (ICDC) for AIP [17] were created, and now, these two types of AIP are referred to as type 1 and type 2 AIP. Diagnosis of type 1 AIP is well established, whereas that of type 2 AIP mainly depends on histological findings, and none of specific serum markers have been identified. Fortunately, both types of AIP generally respond well to corticosteroid treatment. A consensus for treatment of AIP, however, has not yet been established. More importantly, the pathophysiology of AIP is largely unknown.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Yoshida K, Toki F, Takeuchi T, et al. Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis. Dig Dis Sci. 1995;40:1561–8.
Nakano S, Takeda I, Kitamura K, et al. Chronic pancreatitis complicated with Sjogren’s syndrome. Vanishing tumor of the abdomen in a patient with Sjogren’s syndrome. Dig Dis. 1978;23(Suppl):75–9.
Nishimori I, Okazaki K, Yamamoto Y, et al. Specific cellular immune responses to pancreatic antigen in chronic pancreatitis and Sjogren’s syndrome. J Clin Immunol. 1993;13:265–71.
Nakazawa T, Ohara H, Yamada T, et al. Atypical primary sclerosing cholangitis cases associated with unusual pancreatitis. Hepatogastroenterology. 2001;48:625–30.
Hamano H, Kawa S, Ochi Y, et al. Hydronephrosis associated with retroperitoneal fibrosis and sclerosing pancreatitis. Lancet. 2002;359:1403–4.
Hamano H, Kawa S, Horiuchi A, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med. 2001;344:732–8.
Yamamoto M, Takahashi H, Sugai S, et al. Clinical and pathological characteristics of Mikulicz’s disease (IgG4-related plasmacytic exocrinopathy). Autoimmun Rev. 2005;4:195–200.
Morgan WS, Castleman B. A clinicopathologic study of “Mikulicz’s disease”. Am J Pathol. 1953;29:471–503.
Kamisawa T, Okamoto A. Autoimmune pancreatitis: proposal of IgG4-related sclerosing disease. J Gastroenterol. 2006;41:613–25.
Umehara H, Okazaki K, Masaki Y, et al. A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. Mod Rheumatol. 2012;22:1–14.
Umehara H, Okazaki K, Masaki Y, et al. Comprehensive diagnostic criteria for Ig4-related disease (IgG4-RD), 2011. Mod Rheumatol. 2012;22:21–30.
Stone H, Khosroshahi A, Deshpande V, et al. Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations. Arthritis Rheum. 2012;64:3061–7.
Pearson RK, Longnecker DS, Chari ST, et al. Controversies in clinical pancreatology: autoimmune pancreatitis. Does it exist? Pancreas. 2003;27:1–13.
Notohara K, Burgart LJ, Yadav D, et al. Idiopathic chronic pancreatitis with periductal lymphoplasmacytic infiltration: clinicopathologic features of 35 cases. Am J Surg Pathol. 2003;27:1119–27.
Zamboni G, Luttges J, Capelli P, et al. Histopathological features of diagnostic and clinical relevance in autoimmune pancreatitis: a study on 53 resection specimens and 9 biopsy specimens. Virchows Arch. 2004;445:552–63.
Otsuki M, Chung JB, Okazaki K, et al. Asian diagnostic criteria for autoimmune pancreatitis: consensus of the Japan-Korea symposium on autoimmune pancreatitis. J Gastroenterol. 2008;43:403–8.
Shimosegawa T, Chari ST, Frulloni L, et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the international association of pancreatology. Pancreas. 2011;40:352–8.
Kosroshahi A, Bloch DB, Deshpande V, et al. Rituximab leads to rapid decline of serum IgG4-related systemic disease. Arthritis Rheum. 2010;62:1755–62.
Hart PA, Topazian MD, Witzig TE, et al. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. Gut. 2013;62:1607–15.
Khosroshahi A, Carruthers MN, Deshpande V, et al. Rituximab for the treatment of IgG4-related disease. Medicine. 2012;91:57–66.
Stone JH. B cell depletion in IgG4-related disease. In: Umehara H, Okazaki K, Stone JH, Kawa S, Kawano M, editors. IgG4-related disease. Tokyo: Springer; 2012. p. 51–7.
Taguchi M, Kihara Y, Nagashio Y, et al. Decreased production of immunoglobulin M and A in autoimmune pancreatitis. J Gastroenterol. 2009;44:1133–9.
Beck LH, Bonegio RGB, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361:11–21.
Bhol K, Natarajan K, Nagarwalla N, et al. Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: A model for autoimmunity. Proc Natl Acad Sci U S A. 1995;92:5239–43.
Zen Y, Fujii T, Harada K, et al. Th2 and regulatory immune reactions are increased in immunoglobulin G4-related sclerosing pancreatitis and cholangitis. Hepatology. 2007;45:1538–46.
Watanabe T, Yamashita K, Fujikawa S, et al. Involvement of activation of toll-like receptors and nucleotide-binding oligomerization domain-like receptors in enhanced IgG4 responses in autoimmune pancreatitis. Arthritis Rheum. 2012;64:914–24.
Kiyama K, Kawabata D, Hosono Y, et al. Serum BAFF and APRIL levels in patients with IgG4-related disease and their clinical significance. Arthritis Res Ther. 2012;14:R86.
Aalberse RC, Schuurman J. IgG4 breaking the rules. Immunology. 2002;105:9–19.
Yamaguchi Y, Kanetsuna Y, Honda K, et al. Characteristic tubulointerstitial nephritis in IgG4-related disease. Hum Pathol. 2012;43:536–49.
Kawano M, Mizushima I, Yamaguchi Y, et al. Immunohistochemical characteristics of IgG4-related tubulointerstitial nephritis: detailed analysis of 20 Japanese cases. Int J Rheumatol. 2012;609795.
Zack DJM, Stempniak M, Wong AL. Localization of an Fc-binding reactivity to the constant region of human IgG4: implications for the pathogenesis of rheumatoid arthritis. J Immunol. 1995;155:5057–63.
Ueno K, Watanabe T, Kawata Y, et al. IgG4-related autoimmune pancreatitis involving the colonic mucosa. Eur J Gastroenterol Hepatol. 2008;20:1181–21.
Koizumi S, Kamisawa T, Kuruma S, et al. Immunoglobulin G4-related gastrointestinal diseases, are they immunoglobulin G4-related disease? World J Gastroenterol. 2013;19:5769–74.
Watanabe T, Maruyama M, Ito T. Two siblings with type 1 autoimmune pancreatitis. Intern Med. 2013;52:895–9.
Kawa S, Ota M, Yoshizawa K, et al. HLA DRB10405-DQB10401 haplotype is associated with autoimmune pancreatitis in the Japanese population. Gastroenterology. 2002;122:1264–9.
Yamamoto M, Takahashi H, Tabeya T, et al. Risk of malignancies in IgG4-related disease. Mod Rheumatol. 2012;22:414–8.
Shiokawa M, Kodama Y, Yoshimura K, et al. Risk of cancer in patients with autoimmune pancreatitis. Am J Gastroenterol. 2013;108:610–7.
Chiba T, Marusawa H, Ushijima T. Inflammation-associated cancer development in digestive organs: mechanisms and roles for genetic and epigenetic modulation. Gastroenterology. 2012;143:550–63.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Chiba, T., Shiokawa, M., Kodama, Y. (2015). Future Perspective. In: Kamisawa, T., Chung, J. (eds) Autoimmune Pancreatitis. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-55086-7_30
Download citation
DOI: https://doi.org/10.1007/978-3-642-55086-7_30
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-55085-0
Online ISBN: 978-3-642-55086-7
eBook Packages: MedicineMedicine (R0)